Enlivex Ltd. (ENLV)
| Market Cap | 4.46M -83.3% |
| Revenue (ttm) | n/a |
| Net Income | 3.19B |
| EPS | 279.32 |
| Shares Out | 19.91M |
| PE Ratio | 0.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 560,289 |
| Open | 0.2202 |
| Previous Close | 0.2156 |
| Day's Range | 0.2100 - 0.2358 |
| 52-Week Range | 0.2100 - 27.1500 |
| Beta | 1.41 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About ENLV
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was forme... [Read more]
Financial Performance
Financial StatementsNews
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Nes-Ziona, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd.
Enlivex Therapeutics registers to sell 10M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 10M ordinary shares. The company is not selling any shares under…
Enlivex Registration statement: Registration filing
Enlivex filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
Enlivex Therapeutics target adjusted to $80 from $20 at H.C. Wainwright
H.C. Wainwright adjusted the firm’s price target on Enlivex Therapeutics (ENLV) to $80 from $20 and keeps a Buy rating on the shares. The firm cites the 1-for-15 reverse split…
Enlivex Transcript: Study update
A premium-priced transaction with the Rain Foundation aims to strengthen future financing and leverage treasury assets, while Rain protocol milestones show rapid trading growth and ambitious projections. Allocetra's phase I/IIa results in osteoarthritis are promising, with an ongoing phase IIb study and RMAT designation supporting accelerated development.
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
As of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE)...
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including i...
Enlivex Therapeutics announces $400M private placement
Enlivex announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400M of ordinary shares at a price…
Enlivex Announces $400,000,000 Private Placement
Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that...
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an up...
Enlivex Therapeutics receives RMAT designation for Allocetra from FDA
Enlivex announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to Allocetra, the company’s clinical-stage immunotherapy, for the treatment of age-related sympt...
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Nes-Ziona, Israel, July 13, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced that the U.S. Food and Drug Administration (...
Enlivex Therapeutics trading halted, news pending
19:50 EDT Enlivex Therapeutics (ENLV) trading halted, news pending
Enlivex Therapeutics announces 1-for-15 reverse split
Enlivex announced a 1-for-15 reverse split of its ordinary shares. Beginning on July 9, the company’s ordinary shares will trade on Nasdaq Capital Market on a split-adjusted basis. Published first…
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split...
Enlivex Slides: Investor presentation
Enlivex has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2026.
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “ Enlivex ” or the “ Company ”), a quality longevity company powered by a prediction markets treasury, today announced...
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an up...
Enlivex Therapeutics announces issuance of Australian patent
Enlivex announced the issuance of an Australian patent. The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of u...
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the...
Enlivex Slides: Investor presentation
Enlivex has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
As a Gold Sponsor of the Paris event, Enlivex will host a curated dinner today for leading institutional asset managers, allocators, and digital asset investors Nes-Ziona, Israel, June 02, 2026 (GLOBE...
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritis Nes-Ziona, Israel, June 01, 2...
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion. Separately, the Rain Foundation recently announced the appointment of five industry leade...
Enlivex comments on $100M commitment to Rain’s prediction market
Enlivex commented on the Rain Foundation’s announcement of a $100M liquidity commitment to Rain’s prediction markets protocol, which currently positions Rain as the third-largest prediction market pro...